Free Trial
Your Portfolio Deserves Better! MarketBeat All Access for Just $149
Upgrade Now
Claim MarketBeat All Access Sale Promotion

IDEXX Laboratories (IDXX) 10K Form and Latest SEC Filings 2026

IDEXX Laboratories logo
$553.58 +7.09 (+1.30%)
Closing price 04:00 PM Eastern
Extended Trading
$551.48 -2.10 (-0.38%)
As of 06:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest IDEXX Laboratories SEC Filings & Recent Activity

IDEXX Laboratories (NASDAQ:IDXX) has submitted 518+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in IDEXX Laboratories's financial statements. The most recent filing was a Form 144 submitted on May 20, 2026.

Form 4
IDEXX LABORATORIES INC /DE Reports Ownership Change on May. 14, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
IDEXX Laboratories Files Current Report on May. 5, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
IDEXX Laboratories Files Quarterly Report on May. 1, 2025

The 10-Q contains IDEXX Laboratories's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

IDEXX Laboratories SEC Filing History

Browse IDEXX Laboratories' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/14/2026 4:00 PM
Britt Irene Chang (1502314) Reporting
IDEXX Laboratories (874716) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 4:00 PM
Claflin Bruce L. (1403694) Reporting
IDEXX Laboratories (874716) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 4:00 PM
ESSIG STUART (1187574) Reporting
IDEXX Laboratories (874716) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 4:00 PM
HOOLEY JOSEPH L (1123847) Reporting
IDEXX Laboratories (874716) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 4:00 PM
IDEXX Laboratories (874716) Issuer
JUNIUS DANIEL M (1094159) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 4:00 PM
IDEXX Laboratories (874716) Issuer
Kingsley Lawrence D (1301427) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 4:00 PM
IDEXX Laboratories (874716) Issuer
Peacock Karen (1786299) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 4:00 PM
IDEXX Laboratories (874716) Issuer
SAMAD SAM (1694295) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 4:01 PM
IDEXX Laboratories (874716) Issuer
Vandebroek Sophie V. (1442078) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 4:10 PM
HOOLEY JOSEPH L (1123847) Reporting
IDEXX Laboratories (874716) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 4:10 PM
IDEXX Laboratories (874716) Issuer
JUNIUS DANIEL M (1094159) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 4:10 PM
IDEXX Laboratories (874716) Issuer
Kingsley Lawrence D (1301427) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 4:10 PM
IDEXX Laboratories (874716) Issuer
Peacock Karen (1786299) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 4:10 PM
IDEXX Laboratories (874716) Issuer
SZOSTAK M ANNE (1094176) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 4:11 PM
IDEXX Laboratories (874716) Issuer
Vandebroek Sophie V. (1442078) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 5:31 AM
IDEXX Laboratories (874716) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/04/2026 4:00 PM
HOOLEY JOSEPH L (1123847) Reporting
IDEXX Laboratories (874716) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/30/2026 9:29 AM
IDEXX Laboratories (874716) Subject
VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by
Form SCHEDULE 13G
03/27/2026 8:52 AM
IDEXX Laboratories (874716) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/26/2026 7:30 AM
IDEXX Laboratories (874716) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/13/2026 3:00 PM
IDEXX Laboratories (874716) Filer
Form PRE 14A
03/03/2026 8:45 PM
Erickson Michael G (2005385) Reporting
IDEXX Laboratories (874716) Issuer
Form 4/A
03/03/2026 3:08 PM
Hunt Nimrata (1800619) Reporting
IDEXX Laboratories (874716) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/26/2026 3:37 PM
IDEXX Laboratories (874716) Subject
MAZELSKY JONATHAN JAY (1556270) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/25/2026 4:48 PM
Hunt Nimrata (1800619) Reporting
IDEXX Laboratories (874716) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/19/2026 5:00 PM
IDEXX Laboratories (874716) Issuer
Vandebroek Sophie V. (1442078) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 5:00 PM
Erickson Michael G (2005385) Reporting
IDEXX Laboratories (874716) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 6:30 PM
Emerson Andrew (2058587) Reporting
IDEXX Laboratories (874716) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 6:30 PM
Erickson Michael G (2005385) Reporting
IDEXX Laboratories (874716) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 6:30 PM
FENNELL GEORGE (1521861) Reporting
IDEXX Laboratories (874716) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 6:30 PM
Hunt Nimrata (1800619) Reporting
IDEXX Laboratories (874716) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 6:30 PM
IDEXX Laboratories (874716) Issuer
Johnson Michael Perkins (1917747) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 6:30 PM
IDEXX Laboratories (874716) Issuer
Lane Michael (1740689) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 6:30 PM
IDEXX Laboratories (874716) Issuer
MAZELSKY JONATHAN JAY (1556270) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 6:31 PM
IDEXX Laboratories (874716) Issuer
Schreck Michael (2004990) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 6:31 PM
IDEXX Laboratories (874716) Issuer
Smith Martin Alexander (1621358) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 6:31 PM
IDEXX Laboratories (874716) Issuer
Underberg Sharon E. (1630353) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2026 5:39 AM
IDEXX Laboratories (874716) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/13/2026 7:33 AM
IDEXX Laboratories (874716) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/03/2025 4:01 PM
IDEXX Laboratories (874716) Issuer
Peacock Karen (1786299) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/10/2025 4:01 PM
Hunt Nimrata (1800619) Reporting
IDEXX Laboratories (874716) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
From the man who predicted 2008 crash… (Ad)

Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel

Watch Porter Stansberry's full briefing and learn how to prepare now
11/03/2025 4:00 PM
HOOLEY JOSEPH L (1123847) Reporting
IDEXX Laboratories (874716) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/03/2025 5:34 AM
IDEXX Laboratories (874716) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/20/2025 6:51 PM
IDEXX Laboratories (874716) Issuer
Peacock Karen (1786299) Reporting
Form 3/A
10/14/2025 4:34 PM
IDEXX Laboratories (874716) Issuer
Peacock Karen (1786299) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/07/2025 6:06 AM
IDEXX Laboratories (874716) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/04/2025 5:20 PM
IDEXX Laboratories (874716) Issuer
MAZELSKY JONATHAN JAY (1556270) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/03/2025 4:56 PM
IDEXX Laboratories (874716) Issuer
Smith Martin Alexander (1621358) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/03/2025 4:55 PM
HOOLEY JOSEPH L (1123847) Reporting
IDEXX Laboratories (874716) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/26/2025 4:00 PM
IDEXX Laboratories (874716) Issuer
SZOSTAK M ANNE (1094176) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2025 3:06 PM
IDEXX Laboratories (874716) Subject
SZOSTAK M ANNE (1094176) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/14/2025 5:00 PM
Erickson Michael G (2005385) Reporting
IDEXX Laboratories (874716) Issuer
Form 3/A
08/14/2025 5:00 PM
Erickson Michael G (2005385) Reporting
IDEXX Laboratories (874716) Issuer
Form 5/A
08/14/2025 5:01 PM
Erickson Michael G (2005385) Reporting
IDEXX Laboratories (874716) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/13/2025 4:17 PM
Hunt Nimrata (1800619) Reporting
IDEXX Laboratories (874716) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/12/2025 5:32 PM
Erickson Michael G (2005385) Reporting
IDEXX Laboratories (874716) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/11/2025 5:00 PM
Emerson Andrew (2058587) Reporting
IDEXX Laboratories (874716) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/08/2025 8:00 PM
Hunt Nimrata (1800619) Reporting
IDEXX Laboratories (874716) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/08/2025 7:37 PM
IDEXX Laboratories (874716) Issuer
Lane Michael (1740689) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/08/2025 7:38 PM
IDEXX Laboratories (874716) Issuer
MAZELSKY JONATHAN JAY (1556270) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/08/2025 3:23 PM
IDEXX Laboratories (874716) Subject
Underberg Sharon E. (1630353) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/06/2025 3:32 PM
Hunt Nimrata (1800619) Reporting
IDEXX Laboratories (874716) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/04/2025 5:30 AM
IDEXX Laboratories (874716) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/18/2025 4:00 PM
HOOLEY JOSEPH L (1123847) Reporting
IDEXX Laboratories (874716) Issuer
Form 3
Initial statement of beneficial ownership of securities  
07/10/2025 6:00 AM
IDEXX Laboratories (874716) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/23/2025 4:00 PM
IDEXX Laboratories (874716) Issuer
SZOSTAK M ANNE (1094176) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)

IDEXX Laboratories SEC Filings - Frequently Asked Questions

IDEXX Laboratories (IDXX) has submitted 518+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

IDEXX Laboratories's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on IDEXX Laboratories's financial statements page.

The most recent filing was a Form 144 submitted on May 20, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:IDXX) was last updated on 5/20/2026 by MarketBeat.com Staff.
From Our Partners